Contacts

MedinCell announces 2018/19 fiscal year results

June 4, 2019

Achievement of all anticipated milestones for programs in development
Product portfolio progression with a first product in clinical trials* phase 3 and another one in phase 2 in the United States, and two programs in regulatory preclinical* studies
Strong cash position, cash usage in line with expectations


Main clinical progressions of the portfolio (more details and post-closing events on page 3)
CNS (Central Nervous System) treatments developed by our partner TEVA, based on our patented technology
• Start of a Phase 3 clinical study in the US
mdc-IRM / TV46000 – investigational long-acting treatment for schizophrenia
• Initiation of preclinical regulatory development activities of a second product (mdc-TJK)

Pain Management
• Start of a Phase 2 clinical trial in the US (safety and activity study)
mdc-CWM – orthopedic postoperative pain and inflammation with AIC
• Start of preclinical regulatory development for a second product
mdc-CMV – a single injection that combines surgical anesthesia and 3 days of analgesia – most advanced internal
program of MedinCell
• Progression of the formulation of a third product
mdc-NVA – chronic pain management
• These products aim at reducing the use of opioids for pain management

Collaboration with the Bill & Melinda Gates Foundation
• Renewed support from the Foundation for the development of a 6-month contraceptive following the promising results of in vivo studies and payment of the second part of the grant – mdc-WWM

Other products in development
• Promising progression in the formulation of a long acting injectable for patient who received an organ
transplant – mdc-GRT
• Launch of the formulation selection for a new product in urology – mdc-DOM

Strengthened financial visibility
• 21.3 M€ in cash and cash equivalents + 0.7 M€ in short-term investments
• 3.9 M€ in non-current financial assets
• 12.5 M€ drawable under conditions from the European Investment Bank loan
• Cash usage from operating activities in line with expectations: 15.9 M€

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.